Tel Aviv - Delayed Quote • ILA
Compugen Ltd. (CGEN.TA)
At close: April 25 at 2:24 PM GMT+3
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
33,459.00
33,459.00
7,500.00
6,000.00
2,000.00
Cost of Revenue
2,004.00
2,004.00
975.00
680.00
60.00
Gross Profit
31,455.00
31,455.00
6,525.00
5,320.00
1,940.00
Operating Expense
44,447.00
44,447.00
41,899.00
40,394.00
33,436.00
Operating Income
-12,992.00
-12,992.00
-35,374.00
-35,074.00
-31,496.00
Net Non Operating Interest Income Expense
3,210.00
3,210.00
1,410.00
869.00
1,723.00
Other Income Expense
-2.00
-2.00
328.00
2.00
75.00
Pretax Income
-9,784.00
-9,784.00
-33,636.00
-34,203.00
-29,698.00
Tax Provision
8,970.00
8,970.00
58.00
--
--
Net Income Common Stockholders
-18,754.00
-18,754.00
-33,694.00
-34,203.00
-29,698.00
Diluted NI Available to Com Stockholders
-18,754.00
-18,754.00
-33,694.00
-34,203.00
-29,698.00
Basic EPS
-0.21
-0.21
-0.39
-0.41
-0.37
Diluted EPS
-0.21
-0.21
-0.39
-0.41
-0.37
Basic Average Shares
87,633.30
87,633.30
86,555.63
84,203.97
79,591.19
Diluted Average Shares
87,633.30
87,633.30
86,555.63
84,203.97
79,591.19
Total Operating Income as Reported
-12,992.00
-12,992.00
-35,374.00
-35,074.00
-31,496.00
Total Expenses
46,451.00
46,451.00
42,874.00
41,074.00
33,496.00
Net Income from Continuing & Discontinued Operation
-18,754.00
-18,754.00
-33,694.00
-34,203.00
-29,698.00
Normalized Income
-18,752.46
-18,752.46
-33,946.56
-34,205.00
-29,773.00
Interest Income
2,960.00
2,960.00
1,437.00
894.00
1,765.00
Interest Expense
--
--
27.00
25.00
42.00
Net Interest Income
3,210.00
3,210.00
1,410.00
869.00
1,723.00
EBIT
-12,992.00
-12,992.00
-35,374.00
-35,074.00
-31,496.00
EBITDA
-12,516.00
-12,516.00
-34,892.00
-34,613.00
-30,781.00
Reconciled Cost of Revenue
2,004.00
2,004.00
975.00
680.00
60.00
Reconciled Depreciation
476.00
476.00
482.00
461.00
715.00
Net Income from Continuing Operation Net Minority Interest
-18,754.00
-18,754.00
-33,694.00
-34,203.00
-29,698.00
Total Unusual Items Excluding Goodwill
-2.00
-2.00
328.00
2.00
75.00
Total Unusual Items
-2.00
-2.00
328.00
2.00
75.00
Normalized EBITDA
-12,514.00
-12,514.00
-35,220.00
-34,615.00
-30,856.00
Tax Rate for Calcs
0.00
0.00
0.00
--
--
Tax Effect of Unusual Items
-0.46
-0.46
75.44
--
--
12/31/2020 - 8/12/2002
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
EVGN.TA Evogene Ltd.
256.20
-1.16%
BLRX.TA BioLineRx Ltd.
16.40
-2.38%
ENLV.TA Enlivex Therapeutics Ltd.
563.70
+9.37%
LIXT Lixte Biotechnology Holdings, Inc.
3.3150
+2.00%
ARTL Artelo Biosciences, Inc.
1.3250
-0.38%
MDXG MiMedx Group, Inc.
6.24
-0.13%
ARDS Aridis Pharmaceuticals, Inc.
0.0581
-10.69%
EVGN Evogene Ltd.
0.6306
-4.08%
PPBT Purple Biotech Ltd
0.5041
+0.82%
LVTX LAVA Therapeutics N.V.
2.7755
+5.13%